AMAG News 17.88 Amag Pharmaceuticals (AMAG)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amag Pharmaceuticals (AMAG) 17.88 $AMAG

AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino Santini
GlobeNewswire - Wed Apr 16, 6:49PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, taking over for Mike Narachi. Mr. Narachi informed the board that, after eight years of service, he has decided not to stand for re-election at this year's upcoming annual shareholder meeting in May 2014. In addition, James R. Sulat has been elected to serve as a new member of the board of directors, effective immediately.

AMAG Pharmaceuticals Has Returned 28.6% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Mon Apr 14, 4:46PM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 28.57% as of today's recent price of $17.26.

AMAG Pharmaceuticals Shares Down 25.1% Since SmarTrend's Sell Call (AMAG)
Comtex SmarTrend(R) - Mon Apr 07, 11:06AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 25.10% as of today's recent price of $18.10.

AMAG Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 4:00PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the 13 Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. ET in New York. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed.

20.5% Return Seen to Date on SmarTrend AMAG Pharmaceuticals Call (AMAG)
Comtex SmarTrend(R) - Mon Mar 31, 9:47AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 20.55% as of today's recent price of $19.20.

AMAG Pharmaceuticals Has Returned 13.7% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Mon Mar 24, 9:27AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 13.72% as of today's recent price of $20.85.

Concise Analysis of the International Intravenous (IV) Iron Drugs Industry
M2 - Tue Mar 11, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8bxct/intravenous_iv) has announced the addition of the "Concise Analysis of the International Intravenous (IV) Iron Drugs Industry" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 20 companies including many key and niche players such as: - Actavis, Inc. - AMAG Pharmaceuticals, Inc. - Fresenius Medical Care AG & Co. - KGaA Galenica Ltd. - Vifor Pharma Ltd. - Luitpold Pharmaceuticals, Inc. - American Regent, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview & Trends 3. Regulatory Overview 4. Overview Of Intravenous (Iv) Iron Drugs 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 20 (including Divisions/Subsidiaries - 22) - The United States (8) - Japan (2) - Europe (4) - Germany (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (8) For more information visit http://www.researchandmarkets.com/research/k8...avenous_iv

Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare
PR Newswire - Thu Mar 06, 10:50AM CST
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Shares of AMAG Down 12.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 28, 9:33AM CST
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 4 months, AMAG Pharmaceuticals has returned 12.64% as of today's recent price of $21.11.

AMAG Pharmaceuticals, Inc. to Participate in the Cowen and Company 34th Annual Healthcare Conference
GlobeNewswire - Thu Feb 27, 8:52AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Cowen and Company 34 Annual Healthcare Conference on Monday, March 3, 2014 at 4:10 p.m. ET in Boston. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed.

AMAG Pharmaceuticals names Edward Jordan as SVP of Sales and Marketing
M2 - Wed Feb 26, 3:16AM CST
Pharmaceutical company AMAG Pharmaceuticals (NasdaqGS:AMAG) reported on Tuesday the election of Edward Jordan as senior vice president of its sales and marketing.

AMAG Pharmaceuticals Appoints Edward Jordan as Senior Vice President of Sales and Marketing
GlobeNewswire - Tue Feb 25, 7:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Edward Jordan as senior vice president of sales and marketing. Mr. Jordan brings to AMAG more than 20 years of experience in U.S. and international pharmaceutical sales and marketing operations. Prior to joining AMAG, Mr. Jordan served as head of sales, marketing, and operations of the women's health division at Teva Pharmaceuticals. In this role he led sales, marketing, training, and sales analytics for their branded pharmaceuticals, over-the-counter products and a medical device.

Mintz Levin Named Biotechnology "Law Firm of the Year- North America" by M&A Today Global Awards
Business Wire - Fri Feb 21, 11:46AM CST
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. announced that it has been recognized by M&A Today's Global Awards as the 2014 "Law Firm of the Year (Biotechnology) - North America." M&A Today's Global Awards program identifies "industry leaders, exemplary teams and distinguished organizations, based on the simple principles of veracity, accuracy and insight."

Study Shows MuGard(R) is More Effective Than Sham-Control at Reducing Mouth and Throat Soreness Associated With Oral Mucositis in Head and Neck Cancer Patients
GlobeNewswire - Tue Feb 18, 7:01AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the publication of data from a multi-institutional trial of MuGard in the online edition of the journal Cancer available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. MuGard is a mucoadhesive hydrogel. The randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing pain associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.

Spanning and CloudLock to Present "How to Prevent Data Loss and Ensure Compliance for Your SaaS Applications"
Business Wire - Thu Feb 13, 8:00AM CST
Spanning Cloud Apps, the leading provider of data backup and recovery for cloud applications, will join CloudLock, the cloud security pioneer and the world's leading cloud data security company, to demonstrate how organizations can proactively take control of their SaaS applications, preventing data loss and maintaining security and compliance. The webinar, "How to Prevent Data Loss and Ensure Compliance for Your SaaS Applications," will feature AMAG Pharmaceuticals. The company will explain how they effectively implemented backup and recovery for Google Apps and are enforcing data loss prevention policies in Google Drive. Attendees will learn how to mitigate the risks of data leakage and loss, while improving business continuity.

AMAG Pharmaceuticals (AMAG) Falls: Crumbles 5.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:38AM CST
AMAG Pharmaceuticals, Inc. (AMAG) saw a big move last session, as the company’s shares fell by more than 5% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for AMAG, as the stock is now down roughly 13% since Jan 15.

AMAG Pharmaceuticals Announces Pricing of $175 Million of 2.50% Convertible Senior Notes Due 2019
GlobeNewswire - Wed Feb 12, 5:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the pricing of $175 million aggregate principal amount of 2.50% Convertible Senior Notes due 2019 (the "notes" in an underwritten public offering (the "offering" registered under the Securities Act of 1933, as amended. The size of the transaction was increased from the previously announced aggregate principal amount of $150 million. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as book-running managers and Cowen and Company, LLC and Robert W. Baird & Co. Incorporated are acting as co-managers for the offering. AMAG has granted the underwriters the option to purchase, exercisable within a 30-day period, up to an additional $25 million principal amount of notes solely to cover over-allotments, if any. The offering is expected to close on February 14, 2014, subject to customary closing conditions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 97

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 30

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 87

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 129

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 176

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Laboratory Filtration Market Expands to $6.55B by 2031

Updated Category News Views 42

A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 38

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 96

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 81

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading

Top 5 Most Recently Viewed Articles

Octopus AIM VCT plc Announces Securities Purchase Update

Updated Category News Views 173

Overview of Recent Securities Purchase by Octopus AIM VCT plc Octopus AIM VCT plc has made a significant move in the investment landscape with its recent transaction involving the purchase of its own securities. This strategic decision, which involved the cancellation of 723,329 ordinary shares, highlights the company's commitment to managing its capital structure...

Continue Reading
Bradford T Whitmore Makes Significant Investment in Ultralife

Updated Category News Views 116

Notable Insider Investment in Ultralife It recently came to light through official filings that Bradford T Whitmore, a Board Member of Ultralife (NASDAQ: ULBI), has made a substantial insider purchase. This move of buying shares resonates with his confidence in the company's growth trajectory. Understanding the Purchase Whitmore's investment entailed the acquisition of...

Continue Reading
Innovative Partnership to Enhance Youth Care in California

Updated Category News Views 202

Transforming Youth Care Through Innovation Qualifacts, a prominent leader in AI-driven electronic health record (EHR) software, has announced an exciting partnership with Open Line Group Homes. This collaboration aims to revolutionize the billing procedures and operational workflows within residential care facilities catering to youth. With the growing need for efficient,...

Continue Reading
Achilles Therapeutics Transfers Key Assets to AstraZeneca

Updated Category News Views 184

Achilles Therapeutics Transfers Key Assets to AstraZeneca - Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - Recently, Achilles Therapeutics plc (ACHL) announced a pivotal deal, transferring the commercial license of essential data and...

Continue Reading
Insights into Opendoor Technologies (OPEN) Market Performance

Updated Category News Views 311

Recent Developments in Opendoor Technologies Stock Opendoor Technologies Inc (NASDAQ: OPEN) has been capturing investors' attention recently, showcasing a compelling rally that illustrates a resurgence of optimism. The stock, known for its dynamic trading patterns, experienced a significant upswing, climbing more than 50% within just a week. This movement brought its...

Continue Reading